KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Unspecified B-Cell Lymphomas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback